Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

TRKA expression and NTRK1 gene copy number across solid tumours.

Mauri G, Valtorta E, Cerea G, Amatu A, Schirru M, Marrapese G, Fiorillo V, Recchimuzzo P, Cavenago IS, Bonazzina EF, Motta V, Lauricella C, Veronese S, Tosi F, Maiolani M, Rospo G, Truini M, Bonoldi E, Christiansen J, Potts SJ, Siena S, Sartore-Bianchi A.

J Clin Pathol. 2018 Oct;71(10):926-931. doi: 10.1136/jclinpath-2018-205124. Epub 2018 May 25.

PMID:
29802225
2.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Sartore-Bianchi A, Amatu A, Bonazzina E, Stabile S, Giannetta L, Cerea G, Schiavetto I, Bencardino K, Funaioli C, Ricotta R, Cipani T, Schirru M, Gambi V, Palmeri L, Carlo-Stella G, Rusconi F, Di Bella S, Burrafato G, Cassingena A, Valtorta E, Lauricella C, Pazzi F, Gambaro A, Ghezzi S, Marrapese G, Tarenzi E, Veronese S, Truini M, Vanzulli A, Siena S.

Target Oncol. 2017 Aug;12(4):525-533. doi: 10.1007/s11523-017-0505-6.

3.

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

Sartore-Bianchi A, Valtorta E, Amatu A, Veronese S, Lauricella C, Bonazzina E, Siravegna G, Truini M, Bardelli A, Siena S.

ESMO Open. 2016 Aug 4;1(4):e000079. eCollection 2016. No abstract available.

4.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC, Sillekens P.

PLoS One. 2016 Sep 29;11(9):e0163444. doi: 10.1371/journal.pone.0163444. eCollection 2016.

5.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.

Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420.

6.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S.

Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3.

7.

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M.

Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9.

8.

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E.

Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607.

9.

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report.

Metro G, Valtorta E, Siggillino A, Lauricella C, Cenci M, Ludovini V, Minenza E, Prosperi E, Ricciuti B, Rebonato A, Bassetti A, Crinò L.

Ecancermedicalscience. 2015 Jul 28;9:559. doi: 10.3332/ecancer.2015.559. eCollection 2015.

10.

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists.

Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24.

PMID:
26209642
11.

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.

Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F.

Ann Oncol. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290. Epub 2015 Jul 7.

PMID:
26153495
12.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. No abstract available.

PMID:
26151329
13.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Nat Med. 2015 Jul;21(7):827.

14.

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A.

Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947.

15.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

16.

Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.

De Cesare M, Lauricella C, Veronese SM, Cominetti D, Pisano C, Zunino F, Zaffaroni N, Zuco V.

Clin Cancer Res. 2014 Feb 15;20(4):995-1006. doi: 10.1158/1078-0432.CCR-13-1684. Epub 2013 Dec 10.

17.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

PMID:
23883922
18.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.

19.

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.

Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F.

Int J Cancer. 2013 Sep 1;133(5):1259-65. doi: 10.1002/ijc.28106. Epub 2013 Mar 16.

20.

[Genomics in cardiological clinical practice: from the individual response to drug therapy and monogenic cardiovascular disorders].

Marziliano N, Orsini F, Veronese S, Colosimo A, Lauricella C, Motta V, Gambacorta M, Mauri F, Ardissino D, Merlini PA.

G Ital Cardiol (Rome). 2010 Oct;11(10):767-8. Italian. No abstract available.

PMID:
21246778
21.

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.

Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S.

J Clin Oncol. 2008 Sep 1;26(25):4217-9. doi: 10.1200/JCO.2008.18.7286. No abstract available.

22.

Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.

Zabetian CP, Lauricella CJ, Tsuang DW, Leverenz JB, Schellenberg GD, Payami H.

Arch Neurol. 2006 Jan;63(1):156-7. No abstract available.

Supplemental Content

Loading ...
Support Center